Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Roh

Showing results (121-130 of 130) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 130 results.
NPJ Breast Cancer|October 30, 2025
Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Grace B Gallagher, et al.
Clinical Breast Cancer|April 1, 2019
Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways StudyVictoria Larsen, William E Barlow, Jun J Yang, et al.
International Journal of Cancer|July 6, 2024
Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
Journal of the National Cancer Institute|November 3, 2025
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancerErin J Aiello Bowles, Kelli O'Connell, Jenna Bhimani, et al.
JCO Clinical Cancer Informatics|February 14, 2025
Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing StudyPeng Wang, Kelli O'Connell, Jenna Bhimani, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 25, 2024
Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast CancerJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
Journal of the National Cancer Institute|May 20, 2026
Response to Yu, Wang, and GeYashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
Journal of the National Cancer Institute|March 5, 2026
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancerYashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
International Journal of Cancer|November 28, 2025
Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settingsPeng Wang, Kelli O'Connell, Jenna Bhimani, et al.
Cancer|February 24, 2026
Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancerMaria J Monroy-Iglesias, Kelli O'Connell, Jenna Bhimani, et al.
Pageof 13

Showing results (121-130 of 130) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 130 results.
NPJ Breast Cancer|October 30, 2025
Understanding the association between body mass index and chemotherapy dose reductions in women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Grace B Gallagher, et al.
Clinical Breast Cancer|April 1, 2019
Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways StudyVictoria Larsen, William E Barlow, Jun J Yang, et al.
International Journal of Cancer|July 6, 2024
Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancerJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
Journal of the National Cancer Institute|November 3, 2025
Associations between age and chemotherapy dose reductions in women with stage I-IIIA breast cancerErin J Aiello Bowles, Kelli O'Connell, Jenna Bhimani, et al.
JCO Clinical Cancer Informatics|February 14, 2025
Methodologic Approach to Defining Comorbidities in a Cohort of Patients With Cancer: An Example in the Optimal Breast Cancer Chemotherapy Dosing StudyPeng Wang, Kelli O'Connell, Jenna Bhimani, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|July 25, 2024
Patient Characteristics Associated with Intended Nonguideline Chemotherapy in Women with Stage I to IIIA Breast CancerJenna Bhimani, Kelli O'Connell, Sonia Persaud, et al.
Journal of the National Cancer Institute|May 20, 2026
Response to Yu, Wang, and GeYashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
Journal of the National Cancer Institute|March 5, 2026
Clinician- and facility-level factors associated with chemotherapy dose reductions in stages I-IIIA breast cancerYashasvini Sampathkumar, Ziad Zakaria, Kelli O'Connell, et al.
International Journal of Cancer|November 28, 2025
Evaluation of methods to identify chemotherapy-related hematologic toxicities in real-world settingsPeng Wang, Kelli O'Connell, Jenna Bhimani, et al.
Cancer|February 24, 2026
Initial chemotherapy dose reductions and subsequent treatment delivery in stage I-IIIA breast cancerMaria J Monroy-Iglesias, Kelli O'Connell, Jenna Bhimani, et al.
Pageof 13